Given the levels of soluble MICA and MICB found in the serum of cancer patients (~100 pg/mL)48, and the concentrations of PBD2G-ADCs at doses currently used in clinical practice (~500 and 700 ng/mL), the efficacy of MICAB1 PBD2G-ADCs should not be affected by the presence of soluble MICA, but further investigations aiming at addressing this point will be needed. This evidence concerns the gene MICB and cancer.